Foundayo is now available through LillyDirect® and telemedicine providers, and is being distributed to all retail pharmacies in the United States.
Foundayo, the only GLP-1 weight loss pill that can be taken once a day at any time without food or water restrictions, starts at $25per month for people with commercial insurance coverage and $149 per month for those paying on their own.
/PRNewswire-HISPANIC PR WIRE/ — Eli Lilly and Company (NYSE: LLY) announced today that Foundayo™ (orforglipron) is now available for adults who are obese or overweight, who also have related medical problems, after being approved by the Food and Drug Administration (FDA) on April 1, 2026. When used along with a low-calorie diet and more physical activity, Foundayo helps people lose excess body weight without regaining it. Foundayo is a once-daily weight loss pill and has no food or water restrictions. People can now access Foundayo through LillyDirect® and telemedicine providers. Its availability is expanding to retail pharmacies in the United States starting today.
“Foundayo delivers significant weight loss, an average of 27 pounds in clinical studies, and we’ve now made it as easy as possible to deliver prescriptions to your home,” said IIya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. “Now, millions of Americans can contact a healthcare professional to determine if Foundayo is right for them and have the medicine delivered to their home through LillyDirect’s free home delivery service, or get it through telemedicine providers or local retail pharmacies.”
Foundayo is available for a starting price of $149 per month, at its lowest dosage, for self-pay individuals.1 Eligible people with commercial insurance and Foundayo coverage could pay as little as $25 per month with the Foundayo Savings Card.2 Furthermore, from 1o As of July 2026, eligible people with Medicare Part D could pay $50 per month for Foundayo. To understand your options, visit www.foundayo.lilly.com/es.
Backed by the rigorous ATTAIN clinical study program, Foundayo is proven to help people lose weight and keep it off. In the ATTAIN-1 study, people who took the highest dose of Foundayo and remained on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) for the placebo group.3 Participants taking Foundayo, regardless of whether they stayed through the conclusion of the study, lost an average of 25 pounds (11.1%) compared to 5.3 pounds (2.1%) for the placebo group.4In the ATTAIN program, Foundayo, at all doses, also led to reductions in many cardiovascular risk markers, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.
The use of Foundayo in combination with other GLP-1 receptor agonist medicines is not recommended. It is unknown whether Foundayo is safe and effective in children. Foundayo may cause thyroid tumors, including thyroid cancer. Stay alert for possible symptoms, such as a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare professional. The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swelling of the abdomen, tiredness, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Consult theIndication and Safety Summary with Warningsthen, in addition to theComplete Prescription Informationythe Medication Guide.
For more information about Foundayo, visit www.foundayo.lilly.com/es. For more information about LillyDirect, visit www.lilly.com/lillydirect
Access to medicines for obesity
Obesity remains one of the few serious chronic diseases that lacks uniform insurance coverage in U.S. health plans. Although new medications are transforming treatment, about half of Americans with employer-sponsored insurance lack coverage for medications intended to control obesity.5As part of Lilly’s commitment to expanding access to obesity medicine and improving its affordability, Lilly has created more self-pay options for individual patients.
About Foundayo(orforglipron)6
Foundayo™ (orforglipron) is approved by the FDA to help adults with obesity, or adults who are overweight and have related medical problems, reduce excess body weight and maintain this reduction over the long term, along with a low-calorie diet and increased physical activity. Foundayo is a small-molecule (non-peptide) glucagon-like peptide 1 receptor agonist taken by mouth once a day at any time with or without food and water.7Orforglipron was discovered by ChugaiPharmaceuticalCo., Ltd. and licensed by Lilly in 2018. In addition to chronic overweight management, orforglipron is also being studied as a possible treatment for type 2 diabetes, obstructive sleep apnea, knee pain caused by osteoarthritis, hypertension, peripheral artery disease, and urinary incontinence caused by stress.
About the ATTAIN-1 and ATTAIN-2 Clinical Study Program
The global ATTAIN Phase 3 clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight in two global registry studies.
ATTAIN-1 (NCT05869903) is a 72-week, randomized, double-blind, placebo-controlled, phase 3 study comparing the efficacy and safety of various doses of orforglipron with the placebo group in obese or overweight adults with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease, who did not have diabetes. The study randomized 3,127 participants from the US, Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan to receive various doses of orforgliprono placebo in combination with a healthy diet and physical activity. The main objective of the study was to demonstrate that orforgliprones was superior to placebo in reducing body weight from baseline after 72 weeks.
ATTAIN-2 (NCT05872620) is a 72-week, randomized, double-blind, placebo-controlled, phase 3 study comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes. The study randomized more than 1,600 participants from the US, Argentina, Australia, Brazil, China, Czech Republic, Germany, Greece, India, South Korea and Puerto Rico to receive multiple doses of orforgliprono placebo in combination with a healthy diet and physical activity. The primary objective of the study was to demonstrate that orforgliprones was superior to placebo in reducing body weight from baseline at 72 weeks.
INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo™(FOUN-DA-YO) is a prescription medicine used along with a low-calorie diet and more physical activity that helps adults with obesity or some overweight adults, who also have overweight-related medical problems, lose excess body weight without gaining it back.
- Foundayon should not be used with another GLP-1 receptor agonist medication.
- It is unknown whether Foundayo is safe and effective in children.
Warnings-Foundayo could cause thyroid tumors, including thyroid cancer. Be alert for possible symptoms, such as a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath. If you have any of these symptoms, talk to your health care professional.
- Do not use Foundayo if you or someone in your family has had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
- Do not use Foundayo if you have Multiple Endocrine Neoplasia Type 2 (MEN2) syndrome.
- Do not use Foundayo if you have had a serious allergic reaction to orforglipro; you are not allergic to any of the ingredients in Foundayo.
Foundayo may cause serious side effects, including:
Inflammation of the pancreas (pancreatitis).Stop using Foundayo and call your health care professional immediately if you experience severe, persistent pain in your stomach area (abdomen), with or without nausea or vomiting. Sometimes you may feel this pain from your abdomen to your back.
Severe stomach problems.Stomach problems, sometimes severe, have been reported in people using Foundayo. Talk to your health care professional if you have severe or persistent stomach problems.
Kidney problems caused by dehydration.Diarrhea, nausea, and vomiting may cause fluid loss (dehydration), which may lead to kidney problems. It’s important to drink fluids to help reduce the risk of dehydration. Tell your healthcare provider right away if you have persistent nausea, vomiting, or diarrhea.
Low blood sugar (hypoglycemia).Your risk of having low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as a sulfonylurea or insulin.Signs and symptoms of low blood sugar may includedizziness or lightheadedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, tremors, tachycardia, anxiety, irritability or mood changes, hunger, weakness or agitation.
Serious allergic reactions.Stop using Foundayo and get medical help right away if you have any of the symptoms of a serious allergic reaction, including swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, severe rash or itching, fainting or dizziness, or tachycardia.
Changes in vision in patients with type 2 diabetes.Talk to your healthcare professional if you experience vision changes during treatment with Foundayo.
Gallbladder problems.Some people have had gallbladder problems while using Foundayo. Talk to your healthcare provider right away if you have symptoms of gallbladder problems, such as upper stomach (abdomen) pain, fever, yellowing skin or eyes (jaundice), or clay-colored stools, among others.
Entry of food or liquid into the lungs during surgery or other procedures that use anesthesia or require deep sleep (deep sedation).Foundayo may increase the chance of food entering the lungs during surgery or other procedures. Tell your healthcare professionals that you are using Foundayo before they schedule you for surgery or other procedures.
Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, abdominal bloating, tiredness, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your health care professional if you have any side effects that bother you or persist.
Talk to your doctor if you have any side effects.You can report side effects to 1-800-FDA-1088 or atwww.fda.gov/medwatch.
Before taking Foundayo
- Tell your health care professional about all the medicines you use.Foundayo may affect how some medicines work, and some medicines may affect how Foundayo works.
- Pregnancy Exposure Registry:There is a pregnancy exposure registry for women who take Foundayo during their pregnancy. The purpose of this registry is to collect information about your health and that of your baby. Talk to your healthcare professional about how you can participate in this registry, or you can contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
- If you take oral birth control pills, talk to your health care professional before taking Foundayo. The effectiveness of birth control pills may decrease while you are taking Foundayo.Your health care professional may recommend another type of birth control for 30 days after you start Foundayo and for 30 days after each dose increase..
- Talk to your health care professional about low blood sugar and how to manage it.Tell your health care professional if you are taking any medications to treat diabetes, including any type of insulin or sulfonylurea.
Review these questions with your healthcare professional:
❑ Do you have other medical conditions, including any disease related to the pancreas or your kidneys, severe liver problems, severe stomach problems such as delayed stomach emptying (gastroparesis), or problems digesting food?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled for surgery or other procedures that use anesthesia or require deep drowsiness (deep sedation)?
❑ Are you pregnant or planning to be? Foundayo could harm your unborn baby.
❑ Are you breastfeeding or do you plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑ Do you take prescription or over-the-counter medicines, vitamins, or herbal supplements?
Administration mode
- Take Foundayo exactly as your healthcare professional tells you.
- Take Foundayo with a low-calorie diet and more physical activity.
- Take Foundayo orally once a day, with or without food.
- Take the tablets whole. Do not break, crush, or chew the pill.
- If you miss a dose, take it as soon as possible.Notomes2dose of Foundayo on the same day.
- Do not take more than 1 pill per day.
- If you forget to take Foundayo for 7 or more consecutive days, call your healthcare professional to talk about restarting your treatment.
- If you take too much Foundayo, call your health care professional or the Poison Control Center at 1-800-222-1222, or go to the nearest hospital emergency room right away.
More information
Foundayo is a prescription medicine available as 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg tablets taken by mouth. Call 1-800-545-5979 or visitfoundayo.lilly.com/es for more information
This summary provides basic information about Foundayo, but does not include everything that is known about this medicine. Read the information that comes with your prescription each time you get a new supply. This information is not a substitute for talking to your doctor. Be sure to talk to your doctor or health care professional about Foundayo and how it is administered. Your doctor is the best person to help you decide if Foundayo is right for you.
AND CON BS APR2026
Foundayo™is a trademark of Eli Lilly and Company.
Footnotes and References
- Only for self-paying people. A prescription is required. Terms apply. Additional taxes and fees may apply. A month is defined as 30 days. For full terms and conditions, you will find more information at foundayo.lilly.com/es.
- Beneficiaries of government programs are excluded. Terms and conditions apply. More information at foundayo.lilly.com/es.
- The efficacy estimate represents effectiveness based on the assumption that all randomized participants remained in the study (with possible interruptions and dose modifications) for the entire 72 weeks without initiating prohibited weight control treatments.6
- The treatment regimen estimate represents the average estimated treatment effectiveness regardless of compliance with study guidelines or initiation of prohibited weight control treatments.6
- International Foundation of Employee Benefit Plans. Pulse Survey: GLP-1 Drugs Corporate Only.Publicadoen2024.Consultadoel5 denoviembre, 2025.https://www.ifebp.org/docs/default-source/pdf/resources—news/pulse-surveys/survey-glp-drugs-2024.pdf.
- Foundayo. Prescription Information. Lilly USA, LLC.
- Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832. https://doi.org/10.1007/s13300-024-01554-1. Epub 2024 Feb 24. PMID: 38402332; PMCID: PMC10951152.
About Lilly
Lilly is a medicine maker that turns science into cures to improve the lives of people around the world. We have been at the forefront of transformative discoveries for almost 150 years. Today our medicines help tens of millions of people around the world. Using the power of biotechnology, chemistry and genetic medicine, our scientists are constantly testing new discoveries to solve some of the most important health challenges around the world, redefining the treatment of diabetes, treating obesity and combating its most devastating long-term effects, advancing the fight against Alzheimer’s disease, solving some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With every step we take toward a healthier world, we are motivated by our mission to improve the lives of millions of people. This includes conducting innovative clinical studies that reflect the diversity of the world we live in, and continuing to work to ensure our medicines are accessible and affordable. For more details, visitLilly.comyLilly.com/news,or follow us onFacebook,InstagramyLinkedIn.P-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo(orforglipron) as a treatment for adults with obesity or certain overweight adults who also have related medical problems, and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there can be no assurance that planned or ongoing studies will be completed as planned, there are no guarantees that the results of studies conducted in the future will match the results of studies conducted to date, that elorforglipron will receive additional regulatory approvals, or that it will be commercially successful. For more information about these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filed with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no obligation to update forward-looking statements to reflect events after the date of this release.
Trademarks and brand names
All trademarks or trade names mentioned in this press release are the property of the company or, to the extent trademarks or trade names belonging to other companies are mentioned in this press release, the property of their respective owners. For convenience purposes only, the trademarks and trade names mentioned in this press release do not include the symbols ® and™, but such references should not be construed as any indication that the company or, to the extent applicable, its respective owners are not enforcing, to the fullest extent under applicable law, the company’s rights or your rights therein. We do not intend that the use or display of trademarks and trade names of other companies imply a relationship with us, or that such companies endorse or sponsor us.
CMAT-20654 04/2026 ©Lilly USA, LLC 2026. All rights reserved.
Logo –https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg
FUENTE Eli Lilly and Company